SCHEMBL3498736

SCHEMBL3498736

CCOC(=O)c1cn2cc(/C=C/c3ccc(C)cc3)ccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.59
POLB P06746 1/20 0.59
RAB9A P51151 5/20 0.54
GAA P10253 2/20 0.50
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
GABRA2 P47869 3/20 0.48
GABRB2 P47870 3/20 0.48
NPC1 O15118 3/20 0.46
RXFP1 Q9HBX9 1/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
KMT2A Q03164 2/20 0.46
TSHR P16473 1/20 0.45
CASP1 P29466 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TGFBR1 P36897 1/20 0.44
CYP1A2 P05177 2/20 0.44
LMNA P02545 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498738 1.00 KDM4E (0.59) KDM4EPOLBRAB9AGAAMAPT
SCHEMBL3498385 0.92 KDM4E (0.56) KDM4EPOLBRAB9AGAAMAPT
SCHEMBL3498388 0.92 KDM4E (0.56) KDM4EPOLBRAB9AGAAMAPT
SCHEMBL3500190 0.91 KDM4E (0.55) KDM4EPOLBRAB9AGAAGABRA2
SCHEMBL3500191 0.91 KDM4E (0.55) KDM4EPOLBRAB9AGAAGABRA2
SCHEMBL3499344 0.90 KDM4E (0.57) KDM4EPOLBRAB9AGAAMAPT
SCHEMBL1638237 0.86 KDM4E (0.61) KDM4EPOLBRAB9AGAAMAPT
SCHEMBL21033604 0.85 KDM4E (0.60) KDM4EPOLBRAB9AGAAMAPT
SCHEMBL871014 0.84 KDM4E (0.69) KDM4EPOLBRAB9AGAAMAPT
SCHEMBL3499952 0.83 PTGS1 (0.49) KDM4EPOLBRAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 KDM4E 2059/4885POLB 4658/4885RAB9A 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.